The putative protective role of hepatitis B virus (HBV) infection from autoimmune disorders

被引:80
|
作者
Ram, Maya [1 ]
Anaya, Juan-Manuel [4 ]
Barzilai, Ori [1 ]
Izhaky, David [1 ]
Katz, Bat-sheva Porat
Blank, Miri [1 ,2 ]
Shoenfeld, Yehuda [1 ,3 ]
机构
[1] Chaim Sheba Med Ctr, Dept Med B, Ctr Autoimmune Dis, IL-52621 Tel Hashomer, Israel
[2] Tel Aviv Univ, Sackler Fac Med, Dept Human Microbiol, Tel Aviv, Israel
[3] Tel Aviv Univ, Sackler Fac Med, Incumbent Laura Schwarz Kip Chair Res Autoimmune, Tel Aviv, Israel
[4] Corp Invest Biol Univ Rosario, Cellular Biol & Immunogenet Unit, Medellin, Colombia
关键词
Autoimmunity; Hepatitis B virus (HBV); Systemic lupus erythematosus (SLE); Multiple sclerosis (MS); Type 1 diabetes (T1D); Rheumatoid arthritis (RA); Sjogren's syndrome (SS); Hepatitis B core antibody (HBcAb);
D O I
10.1016/j.autrev.2008.06.008
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: The etiology of autoimmune diseases is not fully clarified and the mechanisms underlying their initiation and progression are still obscure. It is becoming clear that in a genetic susceptible individual an environmental trigger such as infectious agent in general and viruses in particular could initiate the development of an autoimmune disease. Hepatitis B virus (HBV) is notorious in its association with diverse autoimmune diseases. Therefore, we aimed to determine the presence of hepatitis B core antibody (HBcAb), a seromarker for past or present infection with HBV, in a large number of sera collected from patients with different autoimmune diseases. Methods: A cohort of 675 sera samples of 5 different autoimmune diseases and healthy donors were screened for evidence of a prior infection with HBV. All samples were tested for hepatitis B core antibody (IgG) using the Monolisa anti-HBc PLUS commercial kit (Bio-Rad, Hercules, San Francisco, USA). Results: Lower percentage of HBcAb was found in sera of the autoimmune diseases when compared to normal controls. Fifteen (10.7%) from 140 normal controls were found positive for the presence of HBcAb. Two (2%) out of 98 multiple sclerosis (MS) sera were positive for the presence of HBcAb (OR: 0.17, 95%CI: 0.03-0.77, p=0.01), 3 (2.5%) out of 117 systemic lupus erythematosus(SLE) sera (OR: 0.2, 95%CI: 0.06-0.77,p=0.01),4(4.5%)out of 89 type 1 diabetes (T1D), 5 (6.1%) from 82 Sjogren's syndrome (SS) sera and 12 (8%) from 149 rheumatoid arthritis (RA) sera were positive for the presence of HBcAb. Conclusions: our data divulge an unexpected low percentage of antibodies to HBcAg in patients with SLE, MS and T1D in comparison to healthy matched donors. This finding may raise a protective role to HBV in some autoimmune diseases i.e. hygiene theory. (C) 2008 Elsevier B.V. All rights reserved.
引用
收藏
页码:621 / 625
页数:5
相关论文
共 50 条
  • [41] HEPATIC EXPRESSION OF HEPATITIS-B VIRUS (HBV) GENOME IN CHRONIC HBV INFECTION
    WU, PC
    FANG, JWS
    LAI, CL
    LAU, SKH
    LO, CK
    LAI, A
    LAU, JYN
    HEPATOLOGY, 1993, 18 (04) : A115 - A115
  • [42] The role of hepatitis B virus (HBV) in the development of hepatocellular carcinoma
    Hildt, E
    Hofschneider, PH
    Urban, S
    SEMINARS IN VIROLOGY, 1996, 7 (05): : 333 - 347
  • [43] Hepatitis B Virus (HBV) Subviral Particles as Protective Vaccines and Vaccine Platforms
    Ho, Joan Kha-Tu
    Jeevan-Raj, Beena
    Netter, Hans-Jurgen
    VIRUSES-BASEL, 2020, 12 (02):
  • [44] Telbivudine (Sebivo) in patients with hepatitis B virus (HBV) chronic infection
    Sacchi, Viola
    FARMECONOMIA-HEALTH ECONOMICS AND THERAPEUTIC PATHWAYS, 2008, 9 (04) : 215 - 218
  • [45] ERYTHEMA-NODOSUM AND HEPATITIS-B VIRUS (HBV) INFECTION
    MAGGIORE, G
    GRIFEO, S
    MARZANI, MD
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1983, 9 (04) : 602 - 603
  • [46] Lamivudine for nephrotic syndrome related to hepatitis B virus (HBV) infection
    Kanaan, N
    Horsmans, Y
    Goffin, E
    CLINICAL NEPHROLOGY, 2006, 65 (03) : 208 - 210
  • [47] HEPATITIS-B VIRUS (HBV) INFECTION IN RENAL DISEASES IN CHILDREN
    DLIN, V
    IGNATOVA, MS
    VASILYEVA, VI
    ASRATIAN, AA
    REIZIS, AR
    ZHURNAL MIKROBIOLOGII EPIDEMIOLOGII I IMMUNOBIOLOGII, 1993, (04): : 108 - 112
  • [49] GANCICLOVIR TREATMENT OF SEVERE HEPATITIS-B VIRUS (HBV) INFECTION
    GISH, RG
    IMPERIAL, JI
    ESQUIVEL, CO
    KEEFFE, EB
    GASTROENTEROLOGY, 1993, 104 (04) : A908 - A908
  • [50] Monitoring patients with a resolved hepatitis B virus infection for HBV reactivation
    Tamori, A.
    Kozuka, R.
    Motoyama, H.
    Fujii, H.
    Hagihara, A.
    Uchida-Kobayashi, S.
    Morikawa, H.
    Enomoto, M.
    Murakami, Y.
    Kawada, N.
    JOURNAL OF HEPATOLOGY, 2018, 68 : S478 - S478